title: Blood transfusion among thalassemia patients: A single Egyptian center experience.
abstract: BACKGROUND
  Although red cell transfusions are lifesavers for patients with thalassemia, they are responsible for a series of complications and expose the patients to a variety of risks.
  
  
  METHODS
  This cross-sectional study included 464 Egyptian beta(β) thalassemia major patients whose age ranged between 10 months and 31 years (mean 10.2 ± 6.6 years). All patients were subjected to thorough history taking with special emphasis on blood transfusions regarding rate of blood transfusion, type of received blood, and history of previous transfusion reactions in addition to type of chelation and compliance to iron chelation therapy and history of diabetes. Serum ferritin and pretransfusion hemoglobin assessment were done for all patients.
  
  
  RESULTS
  The mean pretransfusion hemoglobin level was 5.7 ± 1.16 g/dl. Allergic reactions were observed in 3.9% of the patients during the period of the study, while the history of previous allergic reaction was given by 72% of the patients. Deferiprone showed better compliance (58.6%) than deferoxamine (26.3%). The prevalence of diabetes was 10.1% among the studied group. On comparing diabetics to nondiabetics, serum ferritin, transfusion intervals, and age were statistically higher among diabetics (P<0.001).
  
  
  CONCLUSIONS
  Lower pretransfusion hemoglobin and high rate of prevalence of diabetes, in addition to better compliance to deferiprone than deferoxamine, were detected among the patients.
authors.affiliation: Department of Pediatrics, Cairo University, Cairo, Egypt.
authors.forename: Lamis A
authors.initials: LA
authors.lastname: Ragab
authors.forename: Mona M
authors.initials: MM
authors.lastname: Hamdy
authors.forename: Iman A
authors.initials: IA
authors.lastname: Shaheen
authors.forename: Rania N
authors.initials: RN
authors.lastname: Yassin
keywords: Iron chelators; allergic transfusion reactions; blood transfusion; β-thalassemia
references.citation: Transfusion. 2007 Oct;47(10):1919-29
references.pmid: 17880620
references.citation: Indian Pediatr. 2006 May;43(5):393-400
references.pmid: 16735760
references.citation: Haematologica. 1990 Sep-Oct;75 Suppl 5:122-7
references.pmid: 2086372
references.citation: Asian J Transfus Sci. 2010 Jul;4(2):94-8
references.pmid: 20859507
references.citation: Med J Malaysia. 2008 Jun;63(2):109-12
references.pmid: 18942294
references.citation: Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:158-69
references.pmid: 19337172
references.citation: Leuk Res. 2007 Dec;31 Suppl 3:S10-5
references.pmid: 18037413
references.citation: Klin Padiatr. 1999 Nov-Dec;211(6):431-7
references.pmid: 10592921
references.citation: Diagn Interv Radiol. 2010 Mar;16(1):59-62
references.pmid: 20027547
references.citation: Pediatr Endocrinol Rev. 2007 Dec;5(2):642-8
references.pmid: 18084158
references.citation: AACN Adv Crit Care. 2009 Apr-Jun;20(2):155-63; quiz 165
references.pmid: 19411873
references.citation: Ann N Y Acad Sci. 2005;1054:40-7
references.pmid: 16339650
references.citation: Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:249-55
references.pmid: 16462705
references.citation: Transfus Apher Sci. 2004 Feb;30(1):41-6
references.pmid: 14746820
references.citation: Med J Aust. 2008 Jan 21;188(2):72-5
references.pmid: 18205577
references.citation: Arch Pathol Lab Med. 2003 Mar;127(3):316-20
references.pmid: 12653575
references.citation: P R Health Sci J. 1997 Sep;16(3):255-8
references.pmid: 9431563
references.citation: East Mediterr Health J. 2007 Jul-Aug;13(4):780-6
references.pmid: 17955759
references.citation: P R Health Sci J. 2001 Sep;20(3):229-35
references.pmid: 11776724